Biologics have been dramatically effective in the treatment of psoriasis and have improved the quality of life of patients. However, to our knowledge, no comprehensive study has been implemented to explore the medical burden created by the administration of biologics. Consequently, we assessed the actual state of the cost burden of patients with psoriasis being treated with biologics in Akita University Hospital. Our results suggested that there were considerable differences in the co-payment of biologics up to the health insurance system. Future studies should carefully consider the cost of biologics from the perspective of the increase in medical expenses.